The ID YOUR IRDSM gene testing initiative is no longer offered at this time.

All test kits that are submitted prior to 1/31/18 will be processed within the terms of the program. Test kits that are submitted after 1/31/18 will be processed as a single-gene test for biallelic RPE65 mutations, provided that they are accompanied by a new consent form and a test requisition form, available here.

Spark Therapeutics provides this test free of charge to U.S. patients who have suspected inherited retinal diseases (IRDs). For more information, please contact Spark Therapeutics Generation Patient ServicesSM at 1-833-SPARK-PS (1-833-772-7577). Please see terms and conditions for the single gene test.